LXEO vs. ALVO, TRML, VYGR, ITOS, HUMA, REPL, CRBU, SLDB, JSPR, and AURA
Should you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Alvotech (ALVO), Tourmaline Bio (TRML), Voyager Therapeutics (VYGR), iTeos Therapeutics (ITOS), Humacyte (HUMA), Replimune Group (REPL), Caribou Biosciences (CRBU), Solid Biosciences (SLDB), Jasper Therapeutics (JSPR), and Aura Biosciences (AURA). These companies are all part of the "biological products, except diagnostic" industry.
Alvotech (NYSE:ALVO) and Lexeo Therapeutics (NASDAQ:LXEO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.
Lexeo Therapeutics has a net margin of 0.00% compared to Lexeo Therapeutics' net margin of -967.97%.
Lexeo Therapeutics received 2 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 36.36% of users gave Alvotech an outperform vote.
In the previous week, Lexeo Therapeutics had 10 more articles in the media than Alvotech. MarketBeat recorded 14 mentions for Lexeo Therapeutics and 4 mentions for Alvotech. Alvotech's average media sentiment score of 0.57 beat Lexeo Therapeutics' score of 0.43 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.
Alvotech presently has a consensus target price of $12.67, indicating a potential downside of 10.48%. Lexeo Therapeutics has a consensus target price of $20.80, indicating a potential upside of 66.40%. Given Alvotech's stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Alvotech.
Lexeo Therapeutics has lower revenue, but higher earnings than Alvotech.
60.7% of Lexeo Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Lexeo Therapeutics beats Alvotech on 11 of the 13 factors compared between the two stocks.
Get Lexeo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexeo Therapeutics Competitors List
Related Companies and Tools
